Arcutis Applies for Kids' Atopic Dermatitis Therapy

 

• ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trials
• Roflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile for up to 56 weeks of treatment
• Approximately 1.8 million children with atopic dermatitis (AD) aged 2 to 5 are topically treated in the United States

https://www.globenewswire.com/news-release/2024/12/16/2997469/0/en/Arcutis-Submits-ZORYVE-roflumilast-Cream-0-05-Supplemental-New-Drug-Application-to-the-FDA-for-the-Treatment-of-Children-Aged-2-to-5-with-Mild-to-Moderate-Atopic-Dermatitis.html